BACKGROUND: Androgen excess is a key pathogenetic mechanism in polycystic ovary syndrome (PCOS), although hyperinsulinism also contributes to androgen secretion. Therapeutic approaches for adult patients not seeking fertility include combined oral contraceptives (COC), antiandrogens (AA) and/or insulin sensitizers, although these practices are supported by limited high-quality evidence.
OBJECTIVE AND RATIONALE:
We aimed to assess the efficacy and safety of these common treatments for PCOS by conducting a meta-analysis of RCTs with the following review questions: Which is the more appropriate therapeutic approach for hyperandrogenic symptoms, hyperandrogenemia, and ovulatory dysfunction in adult women with PCOS not seeking fertility; What is the impact on classic cardiometabolic risk factors of the more common treatments used in those women; Does the combination of the antiandrogenic therapy plus metformin have any impact on efficacy or cardiometabolic profile?
SEARCH METHODS: We searched PubMed and EMBASE for articles published up to 16 September 2017. After deleting duplicates, the abstracts of 1522 articles were analysed. We subsequently excluded 1446 articles leaving 76 studies for full-text assessment of eligibility. Of them, 43 articles were excluded. Hence, 33 studies and 1521 women were included in the quantitative synthesis and in the metaanalyses. Meta-analyses calculated mean differences (MD), standardized mean differences (SMD), odds ratio (OR) and 95% CIs. Heterogeneity and inconsistency across studies was assessed by χ 2 test and Higgins's I 2 statistics. Quality and risk of bias of individual studies were assessed according to the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. We then used the approach recommended by the Grading of Recommendations, Assessments, Development, and Evaluation (GRADE) group to indicate the global quality of evidence for a selection of primary outcomes.
Introduction
Polycystic ovary syndrome (PCOS) is a reproductive and endocrine disorder that affects premenopausal women with a worldwide prevalence ranging from 5% to 13% under different diagnostic criteria, almost reaching the figures for type 2 diabetes mellitus (Asuncion et al., 2000; Sanchon et al., 2012; Yildiz et al., 2012; Bozdag et al., 2016) . Excessive androgen biosynthesis and secretion by ovarian theca cells is a key pathogenetic mechanism of PCOS (Wickenheisser et al., 2006; de Medeiros et al., 2015) yet most patients presenting with weight excess and especially those showing hyperandrogenic phenotypes also have insulin resistance (Diamanti-Kandarakis and Dunaif, 2012; Moghetti et al., 2013) . Insulin resistance and its compensatory hyperinsulinism enhance ovarian and adrenal androgen secretion (Diamanti-Kandarakis and Dunaif, 2012; Wu et al., 2014) . In turn, androgen excess favours visceral fat deposition (Lim et al., 2012; Borruel et al., 2013; Dumesic et al., 2016) and possibly adypocite dysfunction (Luque-Ramírez et al., 2008a,b; Martínez-García et al., 2012; Chazenbalk et al., 2013) thereby worsening the insulin resistance and hyperinsulinism (Manneras-Holm et al., 2011; Moghetti et al., 2013; Cassar et al., 2016) . Hence, hyperandrogenism, dysfunctional adiposity and insulin resistance contribute to increased cardiometabolic risk in these women (Randeva et al., 2012; Lim et al., 2013) .
Regarding classic cardiovascular risk factors, when compared with the general female population women with PCOS show increased prevalences of dysglycemia Gambineri et al., 2012; Joham et al., 2014a,b) , dyslipidemia (Wild et al., 2011) , metabolic syndrome , and hypertension (Luque-Ramírez et al., 2014; Joham et al., 2014a,b; Palomba et al., 2015) . Premenopausal women with PCOS are also at an increased risk of endometrial cancer (Barry et al., 2014) because chronic anovulation results in uterine exposure to oestrogens unopposed by progesterone.
Accordingly, the goals of therapy in adult women with PCOS not seeking fertility include amelioration of hyperandrogenic dermo-cosmetic complaints, prevention of endometrial hyperplasia/adenocarcinoma, and prevention or early treatment of cardiometabolic disturbances. At least in theory, these goals may be accomplished by targeting both androgen excess and/or insulin resistance (Luque-Ramirez and EscobarMorreale, 2015) .
Lifestyle management is recommended for all patients with PCOS Legro et al., 2013; Conway et al., 2014a,b; Goodman et al., 2015) . However, although lifestyle intervention improves body composition, cardiorespiratory fitness, and insulin resistance Moran et al., 2011; Harrison et al., 2012; Haqq et al., 2015; Scott et al., 2017) , the effect on hyperandrogenemia and hirsutism is largely unsatisfactory , Domecq et al., 2013 . Furthermore, the impact of lifestyle modification on long-term endometrial protection remains unknown.
Combined oral contraceptives (COC), adding an antiandrogen (AA) in the subset of patients with severe hyperandrogenic symptoms or those who show a suboptimal response to COC, are effective for cosmetic complaints such as hirsutism or acne (Arowojolu et al., 2012; Escobar-Morreale et al., 2012; Legro et al., 2013; van Zuuren et al., 2015) . COC reduce the bioavailability of circulating free testosterone by decreasing gonadotrophin secretion and by increasing the hepatic secretion of sex hormone-binding hormone Zimmerman et al., 2014) . Besides, the use of a COC confers long-term protection againsts endometrial cancer in the general population (Collaborative Group on Epidemiological Studies on Endometrial Cancer, 2015). Thus, for decades, COC and AA have been the first-line therapy for most adult women with PCOS not seeking fertility (Ehrmann, 2005) .
However, certain progestins and the oestrogenic component of contraceptives may worsen insulin sensitivity in women from the general population, particularly when given orally (Godsland et al., 1990; Meyer et al., 2007; Sitruk-Ware and Nath, 2013) . Moreover, COC increase the relative risk of thromboembolic and cardiovascular disease (Lidegaard et al., 2012; de Bastos et al., 2014) , a worrisome issue in women already at risk of cardiovascular morbidity such as those with PCOS (Yildiz, 2015) . Therefore, insulin sensitizers have been proposed as a safer therapeutic alternative, despite being largely ineffective for hirsutism (Cosma et al., 2008; van Zuuren et al., 2015) .
In a Cochrane review of 38 RCTs including 3495 women, metformin improved ovulation rates compared with placebo, but these results could not be confirmed in the subgroup analysis of non-obese or obese women (Tang et al., 2012) . Moreover, metformin was slightly superior to placebo in decreasing waist-to-hip ratio, systolic blood pressure, total testosterone levels, fasting glucose and fasting insulin in non-obese patients (Tang et al., 2012) .
In another recent meta-analysis of 12 RCTs including 608 women (Naderpoor et al., 2016) , metformin plus lifestyle modification increased the number of menstrual cycles compared with lifestyle plus placebo after 6 months of intervention. However, this systematic review failed to reveal any significant impact of adding metformin to lifestyle intervention on BMI, clinical hyperandrogenism, hyperandrogenemia, lipids, insulin sensitivity or blood pressure parameters (Naderpoor et al., 2016) .
In addition, the evidence supporting insulin sensitizers being safer compared with COC is limited (Costello et al., 2007 , Cosma et al., 2008 . A recent trial, however, showed that the addition of metformin to COC may be superior to COC alone on hirsutism, BMI, body composition, hyperandrogenemia and fasting insulin levels after 12 months of treatment (Glintborg et al., 2014a,b) . Furthermore, there are a very few RCTs comparing other insulin sensitizers, such as thiazolidinediones or inositols, with COC alone or their combination (Lemay et al., 2006 , Ozay et al., 2016 .
Review questions
Aiming to assess the efficacy and impact on cardiometabolic risk factors of these common treatments for PCOS, we have conducted a meta-analysis of the RCTs conducted to date with the aim of answering the following questions: Which is the more appropriate drug regimen for hyperandrogenic symptoms, hyperandrogenemia and ovulatory dysfunction in adult women with PCOS not seeking fertility? What is the impact of drugs commonly used for PCOS (COC and AA or insulin sensitizers) on classic cardiometabolic risk factors? Does the addition of metformin to antiandrogenic therapy have any advantage on efficacy or cardiometabolic profiles compared with antiandrogenic therapy alone?
Methods
We followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for systematic reviews and meta-analyses Shamseer et al., 2015) and the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (Higgins and Green, 2011).
Data sources and searches
We searched the PubMed and EMBASE online facilities for articles published up to 16 September 2017 introducing as MESH terms [All Fields] . Full details of the search strategy are provided in Supplementary Data.
Study selection
The reference lists of the articles selected were checked by authors to identify any grey literature and/or studies that were missed by the primary search. The terms were combined with the Cochrane MEDLINE filter for controlled trials of interventions. [Adult] . The searches were re-run just before the final analyses and further studies retrieved for inclusion.
Study population

Type of studies
Parallel or cross-over RCTs (only available data before wash-out period were included) with at least 3 months of follow-up. We did not include articles not written in English.
Participants
Women not seeking fertility with a strict diagnosis of PCOS according to the 2012 National Institute of Health (NIH) criteria (2012) that are inclusive of the earlier 1990 National Institute of Child Health and Human Development criteria (classic phenotype consisting of women presenting with hyperandrogenism and ovulatory dysfunction) (Zawadzki and Dunaif, 1992) , the ESHRE/American Society for Reproductive Medicine (ASRM) definition (2004), and the Androgen Excess & PCOS Society (AE-PCOS) criteria (Azziz et al., 2009) . At least 80% of study population had to be ≥18 years old. Hence, for studies reporting data from adolescents, we estimated whether or not the 20th percentile of age of the sample was ≥18 years old from the mean age and its SD.
Interventions
We conducted meta-analyses in studies comparing antiandrogenic therapy such as COC and/or AA (cyproterone acetate, spironolactone, flutamide or finasteride) alone or in combination versus insulin sensitizers such as metformin, thiazolidinediones, and inositols, alone or in combination with antiandrogenic therapy. Concurrent use of other drugs (i.e. corticoides) were not allowed, yet oligoelements and/or vitamins were accepted.
Meta-analyses were conducted only for markers reported in two or more original studies. Finally, to avoid over-representation of cases, when several studies on the same series of patients have been published, only the report with the larger sample size was included in the meta-analyses. Study selection was performed independently by two investigators (L.N. C. and A.O.F.). Disagreements were discussed and resolved by consensus or by arbitration with an author not involved in the search of the literature (M.L.-R).
Outcomes
Efficacy
The primary outcomes were hirsutism (hirsutism score and/or hair diameter) and menstrual regularity. The secondary outcomes were acne degree, total testosterone, free testosterone, free androgen index (FAI), androstenedione and dehydroepiandrosterone-sulphate concentrations.
Cardiometabolic risk factors
The primary outcomes were BMI, fasting glucose, plasma glucose 2 h after a standard oral glucose tolerance test (OGTT), insulin sensitivity [insulin sensitivity index (ISI) from OGTT, quantitative insulin sensitivity check index (QUICKI) or M-value during euglycemic hyperinsulinemic clamp], homoeostasis model assessment of insulin resistance (HOMA-IR), frequency of glucose tolerance abnormalities, low density-lipoprotein (LDL) cholesterol, high density-lipoprotein (HDL) cholesterol, triglycerides, systolic and diastolic blood pressure, frequency of arterial hypertension.
The secondary outcomes were waist circumference, waist-to-hip ratio (WHR), fasting insulin, area under the curve of insulin and glucose during the OGTT, fasting glucose/insulin ratio, total cholesterol.
Data extraction
M.L.-R. extracted the following data from the retrieved studies included in the meta-analysis: authors' names, publication date, country, sample size, diagnostic criteria for PCOS, study design and duration, intervention, mean and SD for continuous variables and events for dichotomuous variables of pre-specified outcomes. Data extraction is fully described in Supplementary Data.
Quality assessment
Two authors (M.L.-R. and H.F.E.-M.) independently assessed the risk of bias of individual studies using the Cochrane Collaboration tool for assessing risk of bias (Higgins and Green, 2011) (see also Supplementary Data). Disagreements over the risk of bias were resolved by consensus or arbitration by L.N.C. when necessary. For each entry, bias was judged 'low risk', 'high risk' or 'unclear risk'. A risk of bias graph plotting the proportion of studies with each of the judgments and a risk of bias summary graph plotting all of the judgments in a cross-tabulation of study by entry, were generated using Review Manager version 5.3 (RevMan 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).
Then, in order to address the quality of evidence derived from our systematic review for primary outcomes separately, after assessing study limitations (risk of bias) as outlined above, we used the Grading of Recommendations, Assessments, Development, and Evaluation (GRADE) system (Guyatt et al., 2008; Andrews et al., 2013) with the requirements specified in the GRADE Handbook for grading the quality of evidence for systematic reviews (http://gdt.guidelinedevelopment.org/app/handbook/ handbook.html). Results were summarized using the GRADEpro GDT free online application (https://gradepro.org, last accessed 30 October 2017).
Statistical analysis
Meta-analyses were performed using the RevMan 5.3 programme (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Whenever possible we calculated post-intervention standardized mean differences (SMD) statistics for continuous variables as a measure of effect size, in order to reduce the variability derived from the differences in the methodology of outcome assessment used in the different studies. We also calculated 95% CIs of the SMD.
In order to interpret reported units of SMD we transformed the effect back to expected change in percentile rank of every outcome for an average women with PCOS on one arm of treatment compared with the other arm of treatment using the Cohen's U3 index. In some studies, changes from baseline differences were the only available data. Change scores address the same intervention effects as MD do using final measurements. Therefore, there is no reason in statistical terms for not combining in a single meta-analysis studies in which outcomes are reported as change-from-baseline scores with studies that report final measurement outcomes, as long as MD instead of SMD are used (Higgins and Green, 2011) . Hence, in some cases both post-intervention scores and differences in the changes observed in the scores were used in the same meta-analysis, and MD and 95% CI were reported. For clarity, individual studies reporting change in scores were appropriately highlighted in the different meta-analyses.
Aiming to provide a straightforward interpretation of the actual different effect among treatments, forest plots of continuous outcomes are shown as absolute differences among them and arrows beneath graphs show if the direction of the effect favoured one or other treatment. The figures below the horizontal axis represent the magnitude of that effect.
Heterogeneity and inconsistency across studies was assessed by χ 2 test and Higgins's I 2 statistics. I 2 > 50% was considered as a substantial heterogeneity. Fixed-effect models were used for variables with low to moderate heterogeneity and random-effect models were applied to variables showing substantial heterogeneity. In random-effect models, the SD of underlying effects across studies was estimated as Tau   2 . For dichotomouous data, results for each study were expressed as odds ratios (OR) with 95% CI and combined for meta-analysis using the Mantel-Haenszel fixedeffect method.
When the meta-analyses included 10 or more studies, we estimated evidence dissemination bias by funnel plot asymmetry and Egger's regression tests using the free software 'Meta-Essentials: Workbooks for meta-analysis' version 1.0. (http://www.erim.eur.nl/research-support/ meta-essentials).
When data were available, separate meta-analyses were performed for non-obese and overweight patients, and meta-analysis were repeated after excluding studies in which AA were used as single drugs and not in combination with COCs. Fig. 1 shows the PRISMA flow chart, from identification of studies to meta-analysis. After deleting duplicates, the abstracts of 1522 articles were analysed. We subsequently excluded 1446 records on the basis of the title or abstract because these articles were undoubtedly not relevant for the present review.
Results
Study selection
The full-text of the remaining 76 articles was assessed for eligibility. Of them, 43 articles were excluded: 10 studies described nonrandomized trials (Mitkov et al., 2005; Aghamohammadzadeh et al., 2010; Hu et al., 2010; Fabregues et al., 2011; Kebapcilar et al., 2011; Lazaro et al., 2011; Minozzi et al., 2011; Naka et al., 2011; Orbetzova et al., 2011; Suvarna et al., 2016) , 10 studies applied interventions different than those analysed here de Zegher, 2004, 2005; Ibanez et al., 2006 Ibanez et al., , 2007 Ibanez et al., , 2008 Ibanez et al., , 2010 Hadziomerovic-Pekic et al., 2010; Mazza et al., 2014; Shayan et al., 2016; Wang et al., 2016) , nine studies included the same series of participants already collected in another study not reporting any new outcome of interest for the review (Morin-Papunen et al., 2003a, b; Hutchison et al., 2008; Luque-Ramírez et al., 2009a, b; Teede et al., 2010; Luque-Ramirez and Escobar-Morreale, 2011; Luque-Ramírez et al., 2011; Glintborg et al., 2014a Glintborg et al., , b, 2015 Glintborg et al., , 2017 , in four studies over 20% of the total study population consisted of adolescent participants (Ibanez and De Zegher, 2003; Allen et al., 2005; Al-Zubeidi and Klein, 2015) , two studies did not report outcomes of interest for the meta-analysis Cakiroglu et al., 2013) , two were only published as a congress abstract (Andreeva et al., 2016; Moretti et al., 2016) , in one study the patients had been followed for only 1 month (Sahin et al., 2004) , and one study was a cross-over trial and outcomes before crossing were not reported (Dardzinska et al., 2014) . We excluded another two articles after not obtaining any response to our query for data clarification from the authors (see Supplementary Data). One of them (Diri et al., 2016) reported dispersion measures as a structural equation modelling. The other (Mhao et al., 2016) did not detail PCOS criteria and participant's ages. Finally, two RCTs could not be included in any meta-analysis because the particular interventions analysed in them were not addressed by any other trial (Lemay et al., 2006; Ozay et al., 2016) .
Hence, 33 studies were included in the quantitative synthesis and in the different meta-analyses (Morin-Papunen et al., 2000 , 2003a  Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart for a systematic review and meta-analysis of combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome. Elter et al., 2002; Harborne et al., 2003; Ganie et al., 2004 Ganie et al., , 2013 Cibula et al., 2005; Lv et al., 2005; Rautio et al., 2005; Gambineri et al., 2006; Meyer et al., 2007; Luque-Ramírez et al., 2007a , b, c, 2008a , b, 2009a Ozgurtas et al., 2008; Wu et al., 2008; Bilgir et al., 2009; Fruzzetti et al., 2010; Kebapcilar et al., 2010; Essah et al., 2011; Kilic et al., 2011; Panidis et al., 2011; Wei et al., 2012; Moro et al., 2013; Muneyyirci-Delale et al., 2013; Christakou et al., 2014; Glintborg et al., 2014a, b; Kaya et al., 2015; Feng et al., 2016; Mehrabian et al., 2016; Alpañés et al., 2017) (Supplementary  Table SI ).
Risk of bias of studies included in the metaanalysis
A plot of the distribution and a summary table of each of the items for assessing the risk of bias are shown in Supplementary Fig. S1 . The main reasons for high risk of bias were no blinding of participants, and personnel (performance bias) and selective reporting (reporting bias). It is also worth noting that more than 50% of studies had an unclear or high risk of biased allocation to interventions likely related to inadequate/unclear concealment prior to assignment. A detailed description of potential sources of bias is shown in the Supplementary Data.
Meta-analyses of primary outcomes
Efficacy
Hirsutism. For the meta-analysis of hirsutism we included only studies with at least a 6-month follow-up, considering that this is the physiological length of the terminal hair cycle and a shorter duration of interventions was unlikely to produce any noticeable result (EscobarMorreale et al., 2012) . The MD between COC and/or AA and metformin were not significant [n = 273; MD (95% CI): −1.08 points (−2.4, 0.2); Overall effect: Z = 1.63, P = 0.10; Heterogeneity: τ 2 = 2.93, χ 2 = 41.62, df = 9, P < 0.00001; I 2 = 78%]. We observed similar results when restricting the analysis to the four studies with 12-month of follow-up, or when excluding studies using COC without AA (data not shown). However, one particular study that included women with severe hirsutism showed contradictory results, with a greater degree of reduction in hirsutism score in those patients on metformin despite mean hair diameters being reduced to a similar degree in both arms of treatment, and those women on COC had a greater reduction at several anatomical sites such as mid-thigh or forearm (Harborne et al., 2003) . After excluding the Harborne et al. (2003) study, the meta-analysis showed a larger decrease in the hirsutism score with COC and/or AA compared with metformin ( Fig. 2A) . Moreover, when studies including an AA with or without COC where compared with metformin, there were significant differences favouring the antiandrogenic therapy too (Fig. 2B ). There were enough data to conduct the meta-analysis separately in PCOS patients with weight excess (three studies, 155 patients) yet MD in hirsutism score between treatments were not significant in this subgroup of patients (data not shown).
The addition of metformin to COC and/or AA (three studies, 196 patients) was similar to COC and/or AA therapy alone on the hirsutism score, regardless of the presence or absence of weight excess (data not shown).
Endometrial protection. Post-intervention OR for the presence or absence of regular menses favoured COC therapy over metformin in the meta-analysis of three studies that reported such data (Fig. 2C) Cardiometabolic risk factors BMI. The reduction in BMI with metformin was larger than with COC and/or AA therapy (Fig. 3A) , and even greater after excluding those studies where the comparator was an AA alone (15 studies, 805 patients) [MD (95% CI): −0.51 kg/m 2 (−0.89, −0.13); χ 2 : 19.8, P = 0.14; I 2 : 29%]. In the separate meta-analysis of non-obese (five studies, 265 patients) and overweight (six studies, 244 patients) subgroups, the MD between treatments was not significant. Moreover, the addition of metformin to COC and/or AA on BMI also benefited patients by inducing a larger decrease in BMI (Fig. 3B ). In the metaanalysis comparing BMI in women submitted to treatment with COC and/or AA or combination of COC and/or AA plus metformin, significant publication bias was found ( Supplementary Fig. S2 ).
Insulin resistance and glucose tolerance. Metformin resulted in smaller HOMA-IR values compared to COC and/or AA (Fig. 4A) , and that effect was virtually identical after excluding studies in which AA were administered as single therapy (nine studies, 538 patients) [MD (95% CI): −0.46 (−0.60, −0.31); χ 2 : 20.8, P = 0.05; I 2 : 42%].
The meta-analysis of the subgroup of non-obese women (three studies, 195 patients) sustained these results [SMD (95% CI): −0.67 (−0.93, −0.41), Cohen's U: −19%; χ 2 : 4.0, P = 0.41; I 2 : 0%]. The addition of metformin to COC and/or AA also decreased HOMA with respect to antiandrogenic therapy alone (Fig. 4B) . However, we found evidence for publication bias in some of the studies included in the meta-analysis ( Supplementary Fig. S2 ). On the contrary, the meta-analysis of the differences between COC and/or AA and metformin on insulin sensitivity did not show statistically significant differences (Fig. 4C) . However, after excluding the studies in which AA were used without COC, metformin increased post-intervention insulin sensitivity compared with COC ± AA (four studies, 151 patients), [SMD (95% CI): 0.45, Cohen's U: 17%; χ 2 : 0.31, P = 0.99, I 2 = 0%]. We did not find significant differences in the meta-analyses of weight subgroups. The addition of metformin to antiandrogenic therapy did not add any benefit on insulin sensitivity (Fig. 4D) . The meta-analysis of the subgroup of overweight women (two studies, 56 patients) also did not show significant differences (data not shown). There were no statistically significant post-intervention SMD in fasting glucose levels between COC and/or AA and metformin (Fig. 5A) . After excluding studies with AA alone as a comparator, there were no significant differences (six studies, 269 patients, data not shown), as was the case in the separate analyses of non-obese women (two studies, 62 patients, data not shown) and overweight women (two studies, 55 patients, data not shown). However, addition of metformin to COC and/or AA yielded a beneficial reduction in fasting glucose concentrations with respect to COC and/or AA therapy alone (Fig. 5B) . Such a beneficial effect was found in the subgroup of non-obese women in combined therapy (three studies, 137 patients The meta-analysis of plasma glucose concentrations measured after 120 min of a standard OGTT showed no significant differences between COC and/or AA and metformin therapies (Fig. 5C ). The exclusion of the studies administering AA without COC did not change these results (two studies, 69 patients, data not shown). The combination of metformin with an antiandrogenic therapy did not yield any advantage either (Fig. 5D) . Finally, the post-intervention OR for abnormal glucose tolerance showed no significant differences between COC and/or AA and metformin (Fig. 5E) although, after excluding studies administering AA without COC, a statistically significant effect against COC therapy was observed [three studies, 93 patients, OR (95% CI): 4.5 (1.4-14.1); overall effect Z = 2.59, P = 0.01; Heterogeneity χ 2 = 1.4, df = 2, P = 0.51; I 2 = 0%]. The meta-analysis of the only two studies (55 patients) that evaluated this outcome in overweight women did not show significant differences between therapies (data not shown). Another two studies (150 patients) comparing an AA (without COC) with the same AA plus metformin showed no differences in the OR for abnormal glucose tolerance (data not shown).
Lipid profile. We found no differences in the impact of COC and/or AA or metformin on LDL-cholesterol, HDL-cholesterol or triglycerides levels ( Supplementary Fig. S3 ). The exclusion of the studies administering AA without COC did not change these results. The separate meta-analyses of overweight women did not show significant MD among treatments in LDL-cholesterol levels (two studies, 137 patients, data not shown), HDL-cholesterol (three studies, 163 patients, data not shown) or triglycerides (three studies, 163 patients, data not shown). Adding metformin to COC and/or AA was no better than COC and/or AA therapy alone on LDL-cholesterol, HDLcholesterol levels (12 studies, 539 patients), or triglycerides (12 studies, 527 patients), in any group of women (data not shown). Blood pressure. No MD were observed in systolic and diastolic blood pressure between metformin and COC and/or AA ( Supplementary  Fig. S4 ), even after excluding the studies administering AA as single drugs (data not shown). The meta-analysis of systolic blood pressure in overweight women (two studies, 138 patients) did not show significant differences either (data not shown). The addition of metformin to COC and/or AA did not show any advantage over COC and/or AA alone on systolic blood pressure or diastolic blood pressure (four studies, 264 patients, data not shown). Also, the two studies that addressed the OR for hypertension of COC and/or AA over metformin did not show statistically significant differences (data not shown).
Meta-analyses of secondary outcomes
As a general rule, COC or/and AA treatment decreased circulating androgen concentrations more profoundly than metformin (Supplementary  Table SII ) and the combination of metformin with COC and/or AA therapy did not result in any additional effect on hyperandrogenemia but in androstenedione levels. There were no statistically significant MD between treatments on waist circumference nor was there any effect of the addition of metformin to COC and/or AA on this outcome (Supplementary  Table SIII) . We observed a larger reduction in WHR with metformin compared with COC and/or AA but only in non-obese women, and no differences were observed in other comparisons and combined therapy did not provide any advantage over each drug alone (data not shown). Metformin was superior to COC and/or AA in decreasing fasting insulin concentrations and the area under the curve of insulin during an OGTT (Supplementary Table SIII) , but these results were not confirmed in the separate meta-analysis of overweight women (data not shown). Combined therapy was not different to COC and/or AA alone on insulin levels either (data not shown). Metformin increased the fasting glucose to insulin ratio to a greater extent than COC and/or AA when considering all patients as a whole irrespective of weight excess, and in the studies addressing combined therapy (Supplementary  Table SIII ), but not in the separate meta-analysis of overweight women (data not shown).
Discussion
Principal findings
Our systematic review collecting the best evidence available to date suggests that antiandrogenic therapy, namely COC and AA, was superior to insulin sensitizers for low-to-moderate hyperandrogenic symptoms, hyperandrogenemia, and endometrial protection in women with PCOS not pursuing pregnancy. A summary of the most relevant findings is shown in Fig. 6 . Addition of metformin to antiandrogenic therapy did not increase efficacy. Regarding cardiometabolic outcomes, metformin therapy improved BMI, insulin sensitivity, and glucose tolerance and, its combination with antiandrogenic therapy provided additional benefits on BMI, fasting glucose levels, and insulin sensitivity with respect to administration of COC and/or AA alone. Finally, we observed no differences among the pharmacologic approaches analysed here on lipid and blood pressure profiles. Two meta-analyses addressing the different effects of these therapies on women with PCOS have been published (Costello et al., 2007; Cosma et al., 2008) . Our present study, albeit conducted almost a decade later and including a much larger number of studies in which PCOS had been diagnosed strictly, shows no major disagreements with these earlier meta-analyses.
Quality of evidence and applicability
The quality of evidence ranged from very low to high according to the GRADE system. Table I shows a summary of the quality of evidence grades for selected primary outcomes. Quality of evidence was very low for prevalence of hypertension and lipid profiles, low for hirsutism, BMI and blood pressure values, and high for endometrial protection and glucose tolerance. Several factors reduced the quality of evidence, but the most important were limitations of the original studies derived from the lack of blinding of both participants and research personnel, and from unexplained heterogeneity between studies in estimates of the treatment effects.
The potential weaknesses of our meta-analyses derived, therefore, from the original limitations of the individual RCTs that have been detailed throughout the manuscript. All but one of the RCTs did not stress the need for dieting and/or exercising during the follow-up, despite lifestyle changes being recommended at the initial visit in many of them. This may have influenced cardiometabolic outcomes and, together with the lack of blinding in all but one study, possibly biased the reported findings. It is also difficult to explain how the only RCT showing a large effect of metformin on hirsutism patient's selfassessments did not find any significant difference with the COC in objective measurements of hair diameter (Harborne et al., 2003) . Drug compliance was not stressed during the intervention in most studies either, a matter of importance for women on metformin considering the relatively large drop-out rate observed among the women taking this drug in several trials (Morin-Papunen et al., 2000; Ganie et al., 2004 Ganie et al., , 2013 Luque-Ramírez et al., 2007a,b,c; Kilic et al., 2011; Moro et al., 2013; Christakou et al., 2014; Glintborg et al., 2014a,b; Alpañés et al., 2017) . Moreover, the duration of interventions was possibly too short in many studies to observe actual changes in hirsutism or certain metabolic outcomes such as dysglycemia. Finally, the present results only apply to adult patients and should not be extrapolated to adolescents with PCOS, for whom treatment strategies based on quality evidence are unfortunately lacking (Al Khalifah et al., 2016) .
Implications for practice
Even although none of the current clinical guidelines for the management of PCOS support the use of metformin as first-line drug for hyperandrogenic symptoms or endometrial protection (Fauser et al., plus metformin in fasting glucose levels. Panel C, SMD between COC and/or AA and metformin in plasma glucose-120 min after a standard oral glucose tolerance test (OGTT). Panel D, SMD between COC and/or AA and the same therapy plus metformin in plasma glucose-120 min after an OGTT. Panel E, odds ratio (OR) for abnormal glucose tolerance comparing COC ± AA therapy versus metformin. * Differences in the change of scores.
2012; Legro et al., 2013; Conway et al., 2014a,b) , a recent survey of clinical practices for the management of PCOS among European endocrinologists brought to light that this insulin sensitizer was the most commonly prescribed drug in patients with the syndrome (Conway et al., 2014a,b) . Furthermore, data from US female residents with private health insurance coverage suggest that over 45% of women with PCOS on COC therapy were taking metformin concomitantly, despite only 15% of them having a claim for diabetes (Bird et al., 2013) . The rationale behind the use of insulin sensitizers in patients with PCOS, particularly metformin, appears to be their presumed superiority over COC and/or AA in terms of amelioration of cardiometabolic risk factors (Goodman et al., 2015) , in spite of the The table was generated using the Grading of Recommendations, Assessments, Development, and Evaluation (GRADEpro) GDT free online application (https://gradepro.org/, last accessed 30 October 2017). Quality of evidence: High quality means that further research is very unlikely to change our confidence in the estimate of effect; moderate quality means that further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality means that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality means that we are uncertain about the estimate.
fact that a negative impact of COCs on the cardiovascular risk factors of women with PCOS still needs to be demonstrated by actual scientific evidence and the long-term cardiovascular effects of these drugs are currently unknown. In contrast, our present data provide the best available evidence to date to support therapeutic decisions at the point of care. According to our analyses, antiandrogenic therapy appeared to be the best choice for symptoms of hyperandrogenism and endometrial protection. Since women with PCOS seeking health care usually show more severe phenotypes than those in the general population (Ezeh et al., 2013; LuqueRamirez et al., 2015; Lizneva et al., 2016) , COC ± AA should possibly remain as first-line therapy for most adult patients not seeking fertility. Moreover, metformin use was not supported by our results for any PCOS-related symptom aside from weight reduction. The combination of COC ± AA and metformin, however, may be indicated in women with weight excess and in those presenting with insulin resistance and/ or abnormal glucose tolerance.
Implications for research
The main implication for future research of the present comprehensive meta-analysis is that PCOS management remains in urgent need of longterm high-quality studies including large samples of women with the syndrome. In this regard, only multi-centre, preferably multi-national, unbiased randomized studies many answer the currently unsolved questions such as: Why do RCTs only show a small effect of COC on hirsutism when clinical experience appears to say the opposite? What is the actual impact of COC administration on the development of dysglycemia? Does metformin, alone or in combination with COC, prevent the development dysglycemia in PCOS patients at risk? Do these drugs work differently in lean patients and women with overweight or obesity? Does the response to these drugs differ across the spectrum of PCOS phenotypes included in current diagnostic classifications?
Such studies, which are justified by the very high prevalence of PCOS worldwide, would definitely need international networks, a much greater involvement of health authorities and, possibly, industry-sponsored research.
Conclusion
Our present results provide scientific evidence to guide the pharmacologic treatment of women with PCOS not seeking immediate fertility. COC and AA are more effective than metformin for hyperandrogenic symptoms and endometrial protection. Their combination with metformin may, however, provide an additional beneficial effect on BMI and glucose tolerance.
Supplementary data
Supplementary data are available at Human Reproduction Update online.
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